Advocate
Resource hub for campaigns, advocacy materials, and tools developed by hepCoalition and partner organizations that can be adapted and used by advocates for local campaigns in their own contexts.
Campaigns
Campaigns include the ongoing efforts that aim to expand affordable treatment and diagnostics access for all who need it.
Liberate Generics!
Ongoing, global campaign working to accelerate equitable access to affordable, generic hepatitis C treatments. More
- About the Campaign
- Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
- Doctors of the World Opposes the Patent on Sofosbuvir
- APN+ Joins MTAAG+ in Congratulating Malaysia on Sofosbuvir Compulsory License
- Hepatitis C Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Nave Not Been Treated
- Activists Demand Affordable Hepatitis C Treatment
- First Hepatitis C Treatment Developed Through South-South Cooperation Registered in Malaysia
- Gilead’s Claim That Generic Purchase of Sofosbuvir Would Lead to Patent Infringement in Brazil Dismissed
- Sofosbuvir Case in Brazil
- LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
- Treatment for Hepatitis C: The Patent System is Standing in the Way of Access to Medicine
Have a Heart, Save My Liver!
Ongoing, global campaign focusing on where the registration of diagnostics and direct-acting antivirals has stalled as well as the slow treatment uptake in low- and middle-income countries. More
- About the Campaign
- Have a Heart, Save My Liver!: Where Are My Diagnostics?
- Who Has Access to Hepatitis C Testing? Liberate Our Diagnostics!
- Access to Hepatitis C Treatment and Care Among People Who Inject Drugs: Failing People Most Disproportionately Affected
- Have a Heart, Save My Liver! Where is the Cure Registered?
- Have a Heart, Save My Liver! Which Countries Restrict Treatment?
- Have a Heart, Save My Liver! Why Hepatitis C Virus Care Remains Inaccessible
Take Action!
The section includes sign-on letters, petitions, and collective statements.
Urgent Call for Continued WHO Leadership on Harm Reduction for People Who Use Drugs
Advocates sent an open letter to WHO Director-General, urging WHO to maintain its strong presence within the harm reduction, human rights and drug policy spaces, and to ensure the continuation of its crucial work in support of people who use drugs. More
EU Drug Policy Campaign 2025: A Call to Invest in a European Health-Based Drug Policy
The EU Drug Policy Campaign 2025, coordinated by C-EHRN, calls for a shift towards a balanced, health-focused, and human rights-based approach to drug policy. More
Advocacy Tools
Advocacy materials and tools developed by hepCoalition and partner organizations that can be adapted and used by advocates for local campaigns in their own contexts. Includes training materials, community monitoring/data collection, and graphics.
WHO’s New Guidance on Maintaining Opioid Agonist Maintenance Treatment as an Essential Health Service
WHO calls on countries, service planners, providers, policy-makers, and all stakeholders involved in treatment and overdose prevention programmes to ensure live-saving interventions are maintained. More
Global State of Harm Reduction: 2025 Update to Key Data
The 2025 update summarises key developments in harm reduction services, funding and drug policy since the launch of the 9th edition of the report in November 2024. More
Policy Statements
The section includes partners’ policy and advocacy statements that can aid activists in their messaging and calls to action.
Addressing Policy Barriers to Scaling up Needle and Syringe Programmes: A Global Call to Action
Scaling up needle and syringe programmes is essential for achieving global infectious disease-elimination goals and improving health outcomes among people who inject drugs. More
EU Drug Policy Campaign 2025: A Call to Invest in a European Health-Based Drug Policy
The EU Drug Policy Campaign 2025, coordinated by C-EHRN, calls for a shift towards a balanced, health-focused, and human rights-based approach to drug policy. More
